Kidney health for everyone everywhere from prevention to detection and equitable access to care

The global burden of chronic kidney disease (CKD) is rapidly increasing with a projection of becoming the 5th most common cause of years of life lost globally by 2040. Aggravatingly, CKD is a major cause of catastrophic health expenditure. The costs of dialysis and transplantation consume up to 3% of the annual healthcare budget in high-income countries. Crucially, however, the onset and progression of CKD is often preventable. In 2020, the World Kidney Day campaign highlights the importance of preventive interventions – be it primary, secondary or tertiary. This complementing article focuses on outlining and analyzing measures that can beimplemented in every country to promote and advance CKD prevention. Primary prevention of kidney disease should focus on the modification of risk factors and addressing structural abnormalities of the kidney and urinary tracts, as well as exposure to environmental risk factors and nephrotoxins. In persons with pre-existing kidney disease, secondary prevention, including blood pressure optimization and glycemic control, should be the main goal of education and clinical interventions. In patients with advanced CKD, management of co-morbidities such as uremia and cardiovascular disease is a highly recommended preventative intervention to avoid or delay dialysis or kidney transplantation. Political efforts are needed to proliferate the preventive approach. While national policies and strategies for non-communicable diseases might be present in a country, specific policies directed toward education and awareness about CKD screening, management and treatment are often lacking. Hence, there is an urgent need to increase the awareness of the importance of preventive measures throughout populations, professionals and policy makers.

kidney diseases, prevention, detection, awareness

1. International Society of Nephrology (2019). 2019 United Nations High Level Meeting on UHC: Moving Together to Build Kidney Health worldwide. Retrieved 20 July 2019. https://www.theisn.org/images/Advocacy_4_pager_2019_Final_WEB_pagebypage.pdf

2. Foreman KJ, Marquez N, Dolgert A et al. Forecasting life expectancy, years of life lost, and all-cause and causespecific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 2018;392(10159):2052–2090. doi: 10.1016/S01406736(18)31694-5

3. Essue BM, Laba TL, Knaul F et al. Economic burden of chronic ill health and injuries for households in low- and middle-income countries. In: Jamison DT, Gelband H, Horton S, et al., eds. Disease Control Priorities Improving Health and Reducing Poverty. 3 ed. Washington, DC: World Bank; 2018:121–143

4. Vanholder R, Annemans L, Brown E et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol 2017;13(7):393–409. doi: 10.1038/nrneph.2017.63

5. Luyckx VA, Tuttle KR, Garcia-Garcia G et al. Reducing major risk factors for chronic kidney disease. Kidney Int Suppl (2011) 2017;7(2):71–87. doi: 10.1016/j.kisu.2017.07.003

6. Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ 2018;96(6):414–22D. doi: 10.2471/BLT.17.206441

7. Tonelli M, Muntner P, Lloyd A et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012;380(9844):807–814. doi: 10.1016/S0140-6736(12)60572-8

8. Kalantar-Zadeh K, Fouque D. Nutritional Management of Chronic Kidney Disease. N Engl J Med 2017;377(18):1765–1776. doi: 10.1056/NEJMra1700312

9. United Nations General Assembly. Political declaration of the third high-level meeting of theGeneral Assembly on the prevention and control ofnon-communicable diseases (2018) Retrieved from https://www.un.org/ga/search/view_doc.asp?symbol=A/73/L.2&Lang=E

10. Lopez AD, Williams TN, Levin A et al. Remembering the forgotten non-communicable diseases. BMC Medicines 2014;12(1):200. doi: 10.1186/s12916-014-0200-8

11. (CDC) Center for Disease Control and Prevention. “Picture of America” (www.cdc.gov/pictureofamerica). At a Glance – Executive Summary. 2017;2019

12. Levey AS, Schoolwerth AC, Burrows NR et al. Centers for Disease Control and Prevention Expert Panel. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis 2009;53(3):522–535. doi: 10.1053/j.ajkd.2008.11.019

13. Saran R, Robinson B, Abbott KC et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 2019;73(3S1):A7–A8. doi: 10.1053/j.ajkd.2019.01.001

14. Kovesdy CP, Furth SL, Zoccali C, World Kidney Day Steering Committee. Obesity and Kidney Disease: Hidden Consequences of the Epidemic. J Ren Nutr 2017;27(2):75–77. doi: 10.1053/j.jrn.2017.01.001

15. Tantisattamo E, Dafoe DC, Reddy UG et al. Current Management of Acquired Solitary Kidney. Kidney International Reports 2019;4(9):1205–1218. doi: 10.1016/j.ekir.2019.07.001

16. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet 2017;389(10075):1238–1252. doi: 10.1016/S0140-6736(16)32064-5

17. Koppe L, Fouque D. The Role for Protein Restriction in Addition to Renin-Angiotensin-Aldosterone System Inhibitors in the Management of CKD. Am J Kidney Dis 2019;73(2):248–257. doi: 10.1053/j.ajkd.2018.06.016

18. Rifkin DE, Coca SG, Kalantar-Zadeh K. Does AKI truly lead to CKD? J Am Soc Nephrol 2012;23(6):979–984. doi: 10.1681/ASN.2011121185

19. Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367(25):2407–2418. doi: 10.1056/NEJMoa1205511

20. Verhave JC, Troyanov S, Mongeau F et al. Prevalence, awareness, and management of CKD and cardiovascular risk factors in publicly funded health care. Clin J Am Soc Nephrol 2014; 9:7139. doi: 10.2215/CJN.06550613

21. Chow KM, Szeto CC, Kwan B et al. Public lacks knowledge on chronic kidney disease: Telephone survey. Hong Kong Med J 2014;20:139–144

22. Ene-Iordache B, Perico N, Bikbov B et al. Chronic kidney diseaseand cardiovascular risk in six regions of the world (ISN-KDDC): Across-sectional study. Lancet Glob Health 2016;4:e307–319

23. Li PKT, Weening JJ, Dirks J et al. A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease. Kidney Int Suppl 2005;(94):s2–7. doi: 10.1111/j.15231755.2005.09401.x

24. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: A position statement from the National Kidney Foundation. Am J Kidney Dis 2007;50:169–180. doi: 10.1053/j.ajkd.2007.06.013

25. Levey AS, Atkins R, Coresh J et al. Chronic kidney disease as a global public health problem: Approaches and initiatives – aposition statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72:247–259. doi: 10.1038/sj.ki.5002343

26. Crowe E, Halpin D, Stevens P. Guideline Development Group. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ 2008;337:a1530. doi: 10.1136/bmj.a1530

27. Li PKT, Chow KM, Matsuo S et al. Asian Chronic Kidney Disease (CKD) Best Practice Recommendations – Positional Statements for Early Detection of CKD from Asian Forum for CKD Initiatives (AFCKDI). Nephrology 2011;16(7):633–641. doi: 10.1111/j.1440-1797.2011.01503.x

28. Fink HA, Ishani A, Taylor BC et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: A systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2012;156:570–581

29. Li PKT, Ng JK, Cheng YL et al. Relatives In Silent Kidney disease Screening study (RISKS): a Chinese cohort study. Nephrology 2017;22(Suppl 4):35–42. doi: 10.1111/nep.13148

30. Samal L, Linder JA. The primary care perspective on routine urine dipstick screening to identify patients with albuminuria. Clin J Am Soc Nephrol 2013;8(1):131–135. doi: 10.2215/CJN.12681211

31. George C, Mogueo A, Okpechi I et al. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Glob Health 2017;2(2):e000256. doi: 10.1136/bmjgh-2016-000256

32. Gonzalez-Quiroz M, Nitsch D, Hamilton S et al. DEGREE Study Steering Committee. Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE). BMJ Open 2019;9:e031169. doi: 10.1136/bmjopen-2019-031169

33. Boulware LE, Jaar BG, Tarver-Carr ME et al. Screening for proteinuria in US adults: A cost-effectiveness analysis. JAMA 2003;290:3101–3114. doi: 10.1001/jama.290.23.3101

34. Go DS, Kim SH, Park J et al. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea. Nephrology 2019;24(1):56–64. doi: 10.1111/nep.13203

35. Komenda P, Ferguson TW, Macdonald K et al. Cost-effectiveness of primary screening for CKD: A systematic review. Am J Kidney Dis 2014;63:789–797. doi: 10.1053/j.ajkd.2013.12.012

36. Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology 2010;15(Suppl.2):3–9. doi: 10.1111/j.1440-1797.2010.01304.x

37. Almaguer M, Herrera R, Alfonso J et al. Primary health care strategies for the prevention of end-stage renal disease in Cuba. Kidney Int Suppl 2005;97:S4–10. doi: 10.1111/j.15231755.2005.09701.x

38. Alamaguer-Lopez M, Herrera-Valdez R, Diaz J, Rodriguez O. Integration of chronic kidney disease prevention into noncommunicable disease programs in Cuba. In G Garcia-Garcia, LY Agodoa, & KC Norris (Eds.), Chronic Kidney Disease in Disadvantaged Populations 2017 (pp. 357–365). London: Elsevier Inc

39. US Department of Health and Human Services. Advancing American Kidney Health., 2019 accessed Sept 26, 2019 https://aspe.hhs.gov/pdf-report/advancing-american-kidney-health

40. US Department of Health and Human Services. The Special Diabetes Program for Indians. Estimates of Medicare savings., 2019. Accessed Sept 26, 2019 https://aspe.hhs.gov/pdf-report/special-diabetes-program-indians-estimates-medicare-savings

41. Bello AK, Nwankwo E, El Nahas AM. Prevention of chronic kidney disease: a global challenge. Kidney Int Suppl 2005;98:S11–17. doi: 10.1111/j.1523-1755.2005.09802.x

42. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010;375(9722):1296–1309

43. Cortés-Sanabria L, Cabrera-Pivaral CE, Cueto-Manzano AM et al. Improving care of patients with diabetes and CKD: a pilot study for a cluster-randomized trial. Am J Kidney Dis 2008;51(5):777–788. doi: 10.1053/j.ajkd.2007.12.039

44. Martínez-Ramírez HR, Jalomo-Martínez B, CortésSanabria L et al. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist. Am J Kidney Dis 2006;47(1):78–87. doi: 10.1053/j.ajkd.2005.09.015

45. Cueto-Manzano AM, Martínez-Ramírez HR, CortesSanabria L, Rojas-Campos E. CKD screening and prevention strategies in disadvantaged populations. The role of primary health care professionals. In G Garcia-Garcia, LY Agodoa, & KC Norrris (Eds.), Chronic Kidney Disease in Disadvantaged Populations 2017 (pp. 329–335). London: Elsevier, Inc

46. Tapia-Conyer R, Gallardo-Rincon H, Betancourt-Cravioto M. Chronic kidney disease in disadvantaged populations: Online educational programs for NCD prevention and treatment. In G Garcia-Garcia, LY Agodoa, & KC Norris (Eds.), Chronic Kidney Disease in Disadvantaged Populations. 2017 (pp. 337–345). London: Elsevier, Inc

47. Bello AK, Levin A, Manns BJ et al. Effective CKD care in European countries: challenges and opportunities for health policy. Am J Kidney Dis 2015;65(1):15–25. doi: 10.1053/j.ajkd.2014.07.033

48. Sharif MU, Elsayed M E, Stack AG. The global nephrology workforce: emerging threats and potential solutions! Clin Kidney J 2016;9(1):11–22. doi: 10.1093/ckj/sfv111

49. Naicker S, Eastwood JB, Plange-Rhule J, Tutt RC. Shortage of healthcare workers in sub-Saharan Africa: a nephrological perspective. Clin Nephrol 2010;74(Suppl 1):S129–133

50. Cusumano AM, Rosa-Diez GJ, Gonzalez-Bedat MC. Latin American Dialysis and Transplant Registry: Experience and contributions to end-stage renal disease epidemiology. World J Nephrol 2016;5(5):389–397

51. Feehally J, Brusselmans A, Finkelstein FO et al. Improving global health: measuring the success of capacity building outreach programs: a view from the International Society of Nephrology. Kidney Int Suppl 2016;6(2):42–51. doi: 10.1016/j.kisu.2016.09.002

52. Harris DC, Dupuis S, Couser WG, Feehally J. Training nephrologists from developing countries: does it have a positive impact? Kidney Int Suppl 2012;2(3):275–278. doi: 10.1038/kisup.2012.32

53. Tisher CC, Bastl CP, Bistrian BR et al. Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Consensus Development Conference Panel. Ann Intern Med 1994;121(1):62–70

54. Garcia-Garcia G, Martinez-Castellanos Y, RenoirteLopez K et al. Multidisciplinary care for poor patients with chronic kidney disease in Mexico. Kidney Int Suppl 2013;3(2):178–183. doi: 10.1038/kisup.2013.9/

55. Stanifer JW, Von Isenburg M, Chertow GM, Anand S. Chronic kidney disease care models in low- and middle-income countries: a systematic review. BMJ Glob Health 2018; 3(2): e000728. doi: 10.1136/bmjgh-2018-000728

56. Narva AS, Norton JM, Boulware LE. Educating Patients about CKD: The Path to Self-Management and Patient-Centered Care. Clin J Am Soc Nephrol 2016;7;11(4):694–703. doi: 10.2215/CJN.07680715

57. Schatell D. Web-based kidney education: supporting patient self-management. Semin Dial 2013;26(2):154–158. doi: 10.1111/sdi.12057